Advertisement
BAX vs MDT
Which Stock Would AI Choose? Baxter International (BAX) vs. Medtronic (MDT) Stock Comparison
Key Takeaways
- Baxter International (BAX) delivered a strong second-quarter 2026 earnings beat and raised full-year guidance, driving a significant post-earnings stock rally amid its ongoing turnaround efforts.
- Medtronic (MDT) reported its strongest annual revenue growth in a decade for fiscal 2026, supported by robust performance in Cardiovascular and new product launches, with upcoming first-quarter results anticipated in early September.
- BAX shares trade at a lower market capitalization and valuation multiple compared to MDT, reflecting differences in scale and growth profiles within the medtech sector.
- Recent market activity shows BAX benefiting from cost-cutting and segment-specific demand, while MDT maintains broader momentum from innovation pipelines and share gains in key therapies.
- Both companies operate in healthcare equipment, exposing them to similar regulatory, reimbursement, and macroeconomic factors, though MDT offers greater diversification across product categories.
- Relative performance highlights trade-offs between BAX’s near-term catalysts from its earnings momentum and MDT’s established scale and consistent dividend growth history.
Introduction
Investors and traders frequently compare Baxter International (BAX) and Medtronic (MDT) as representative names in the medtech space, where both companies develop and manufacture medical devices and therapies. This comparison provides insights into relative performance, business positioning, and market sentiment for those evaluating healthcare sector allocations or seeking exposure to companies navigating innovation cycles and operational improvements. Participants ranging from institutional portfolio managers to individual traders monitoring earnings-driven volatility may find the analysis relevant when assessing diversification within medical products and therapies.
BAX Overview and Recent Performance
Baxter International (BAX) is a global medical products company focused on infusion therapies, drug compounding, advanced surgery, and related healthcare solutions. In recent market activity, the company reported second-quarter 2026 results that exceeded expectations, with sales rising 5% on both reported and organic bases to $2.96 billion. Adjusted earnings per share reached $0.56, surpassing analyst estimates, aided by strength in its medical products and therapies segment. Management raised full-year 2026 guidance for sales growth and adjusted earnings, citing progress on cost structure actions and volume improvements. The stock experienced notable appreciation following the July earnings release, reflecting positive investor response to the operational updates, though broader sector dynamics continue to influence price behavior.
MDT Overview and Recent Performance
Medtronic (MDT) is a leading medical technology company offering a wide range of devices across cardiovascular, neuroscience, diabetes, and surgical portfolios. Recent market activity reflects continued momentum from its fiscal 2026 results, which included the highest annual revenue growth in ten years at 8.4% reported. The company has highlighted gains in Cardiac Ablation Solutions and other innovation-driven areas. As of late August 2026, shares traded near $91 amid mixed year-to-date performance but positive movement in the most recent month. With first-quarter fiscal 2027 earnings scheduled for early September, analysts have noted potential for further updates on product adoption and guidance, contributing to ongoing sentiment around the stock’s positioning.
Trending AI Robots
Tickeron’s Trending AI Robots page showcases a curated selection of AI trading bots from hundreds available across the platform. These bots trade thousands of different tickers using varied strategies, timeframes, performance metrics, and risk parameters, with only those demonstrating suitability for prevailing market conditions featured in the trending section. Available bots display a range of historical win rates, average returns per trade, and drawdown statistics that traders can review to match their preferences. The section serves as a resource for exploring automated approaches without favoring any single methodology. Users interested in current trending options can visit the Trending AI Robots page for additional details.
Head-to-Head Comparison
Baxter International (BAX) and Medtronic (MDT) differ substantially in scale, with MDT maintaining a significantly larger market capitalization and broader product diversification across multiple therapeutic areas. BAX emphasizes targeted segments such as infusion therapies and drug compounding, where recent demand has supported its turnaround initiatives and guidance revisions. In contrast, MDT benefits from established leadership in high-growth areas like pulsed field ablation and robotic-assisted surgery, contributing to its longer-term revenue trajectory. Risk factors for BAX include execution on cost controls and resolution of legacy issues, while MDT faces typical medtech challenges around regulatory approvals and competitive pressures in innovation cycles. Market sentiment has recently favored BAX’s near-term earnings surprise, whereas MDT’s positioning reflects sustained analyst interest in its pipeline. Sector exposure remains comparable, though MDT’s global footprint and dividend consistency provide different trade-offs relative to BAX’s more concentrated recovery narrative.
Tickeron AI Verdict
Based on observable factors such as trend consistency following earnings updates, stability in guidance revisions, and relative positioning within the medtech sector, Tickeron’s AI may currently assign a probabilistic preference toward Medtronic (MDT). The company’s demonstrated multi-quarter growth drivers and broader innovation pipeline provide a foundation for steadier momentum compared to Baxter International (BAX)’s more event-driven recent activity. This assessment draws from verifiable performance patterns and does not constitute investment advice.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is BAX is a StrongBuy and MDT is a StrongBuy.
| BAX | MDT | BAX / MDT | |
| Capitalization | 12.3B | 116B | 11% |
| EBITDA | 762M | 10.3B | 7% |
| Gain YTD | 24.716 | -3.675 | -673% |
| P/E Ratio | 87.85 | 22.40 | 392% |
| Revenue | 11.5B | 37.5B | 31% |
| Total Cash | 2.15B | 8.82B | 24% |
| Total Debt | 9.67B | 28.2B | 34% |
BAX | MDT | ||
|---|---|---|---|
OUTLOOK RATING 1..100 | 58 | 84 | |
VALUATION overvalued / fair valued / undervalued 1..100 | 98 Overvalued | 4 Undervalued | |
PROFIT vs RISK RATING 1..100 | 100 | 100 | |
SMR RATING 1..100 | 94 | 68 | |
PRICE GROWTH RATING 1..100 | 47 | 47 | |
P/E GROWTH RATING 1..100 | 26 | 59 | |
SEASONALITY SCORE 1..100 | 85 | n/a |
Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.
MDT's Valuation (4) in the Medical Specialties industry is significantly better than the same rating for BAX (98). This means that MDT’s stock grew significantly faster than BAX’s over the last 12 months.
MDT's Profit vs Risk Rating (100) in the Medical Specialties industry is in the same range as BAX (100). This means that MDT’s stock grew similarly to BAX’s over the last 12 months.
MDT's SMR Rating (68) in the Medical Specialties industry is in the same range as BAX (94). This means that MDT’s stock grew similarly to BAX’s over the last 12 months.
MDT's Price Growth Rating (47) in the Medical Specialties industry is in the same range as BAX (47). This means that MDT’s stock grew similarly to BAX’s over the last 12 months.
BAX's P/E Growth Rating (26) in the Medical Specialties industry is somewhat better than the same rating for MDT (59). This means that BAX’s stock grew somewhat faster than MDT’s over the last 12 months.
| BAX | MDT | |
|---|---|---|
| RSI ODDS (%) | 3 days ago 65% | 3 days ago 52% |
| Stochastic ODDS (%) | 3 days ago 62% | 3 days ago 54% |
| Momentum ODDS (%) | 3 days ago 67% | 3 days ago 54% |
| MACD ODDS (%) | 3 days ago 70% | 3 days ago 68% |
| TrendWeek ODDS (%) | 3 days ago 66% | 3 days ago 55% |
| TrendMonth ODDS (%) | 3 days ago 71% | 3 days ago 50% |
| Advances ODDS (%) | 26 days ago 57% | 10 days ago 53% |
| Declines ODDS (%) | 3 days ago 66% | 3 days ago 56% |
| BollingerBands ODDS (%) | 3 days ago 71% | 3 days ago 54% |
| Aroon ODDS (%) | 3 days ago 56% | 3 days ago 36% |
Long-Term Analysis
It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is overvalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).
BAX’s FA Score shows that 1 FA rating(s) are green while MDT’s FA Score has 1 green FA rating(s).
- BAX’s FA Score: 1 green, 4 red.
- MDT’s FA Score: 1 green, 4 red.
Short-Term Analysis
It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.
If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.
BAX’s TA Score shows that 4 TA indicator(s) are bullish while MDT’s TA Score has 4 bullish TA indicator(s).
- BAX’s TA Score: 4 bullish, 5 bearish.
- MDT’s TA Score: 4 bullish, 4 bearish.
Price Growth
BAX (@Pharmaceuticals: Other) experienced а -7.86% price change this week, while MDT (@Medical/Nursing Services) price change was -3.41% for the same time period.
The average weekly price growth across all stocks in the @Pharmaceuticals: Other industry was -3.51%. For the same industry, the average monthly price growth was -3.46%, and the average quarterly price growth was +12.67%.
The average weekly price growth across all stocks in the @Medical/Nursing Services industry was -5.01%. For the same industry, the average monthly price growth was -8.95%, and the average quarterly price growth was -6.66%.
Reported Earning Dates
BAX is expected to report earnings on Oct 29, 2026.
MDT is expected to report earnings on Nov 24, 2026.
Industries' Descriptions
@Pharmaceuticals: Other (-3.51% weekly)Pharmaceuticals (Other) comprise companies that are involved in the discovery, development or manufacturing of therapeutic and preventative medicines. They often collaborate with or acquire other pharmaceutical/healthcare firms. Examples of companies in this segment include Bausch Health Companies Inc., Icon Plc and Perrigo Company Plc.
@Medical/Nursing Services (-5.01% weekly)The medical/nursing services includes companies that provide medical-related services such as ambulance services, dialysis centers, respiratory therapy, blood testing and rehabilitation services. DaVita Inc., Chemed Corporation and Guardant Health, Inc. are examples of companies in this industry.
Advertisement
MDT and
Correlation & Price change
A.I.dvisor indicates that over the last year, MDT has been loosely correlated with SYK. These tickers have moved in lockstep 59% of the time. This A.I.-generated data suggests there is some statistical probability that if MDT jumps, then SYK could also see price increases.